377 related articles for article (PubMed ID: 37749625)
1. Focal adhesion kinase: from biological functions to therapeutic strategies.
Tan X; Yan Y; Song B; Zhu S; Mei Q; Wu K
Exp Hematol Oncol; 2023 Sep; 12(1):83. PubMed ID: 37749625
[TBL] [Abstract][Full Text] [Related]
2. Targeting focal adhesion kinase in cancer cells and the tumor microenvironment.
Murphy JM; Rodriguez YAR; Jeong K; Ahn EE; Lim SS
Exp Mol Med; 2020 Jun; 52(6):877-886. PubMed ID: 32514188
[TBL] [Abstract][Full Text] [Related]
3. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Lu Y; Sun H
J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
[TBL] [Abstract][Full Text] [Related]
4. Focal adhesion kinase inhibitors, a heavy punch to cancer.
Wu Y; Li N; Ye C; Jiang X; Luo H; Zhang B; Zhang Y; Zhang Q
Discov Oncol; 2021 Nov; 12(1):52. PubMed ID: 35201485
[TBL] [Abstract][Full Text] [Related]
5. FAK in Cancer: From Mechanisms to Therapeutic Strategies.
Chuang HH; Zhen YY; Tsai YC; Chuang CH; Hsiao M; Huang MS; Yang CJ
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163650
[TBL] [Abstract][Full Text] [Related]
6. Emerging roles of focal adhesion kinase in cancer.
Tai YL; Chen LC; Shen TL
Biomed Res Int; 2015; 2015():690690. PubMed ID: 25918719
[TBL] [Abstract][Full Text] [Related]
7. Targeting FAK in human cancer: from finding to first clinical trials.
Golubovskaya VM
Front Biosci (Landmark Ed); 2014 Jan; 19(4):687-706. PubMed ID: 24389213
[TBL] [Abstract][Full Text] [Related]
8. Roles and inhibitors of FAK in cancer: current advances and future directions.
Hu HH; Wang SQ; Shang HL; Lv HF; Chen BB; Gao SG; Chen XB
Front Pharmacol; 2024; 15():1274209. PubMed ID: 38410129
[TBL] [Abstract][Full Text] [Related]
9. Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence.
Quispe PA; Lavecchia MJ; León IE
Drug Discov Today; 2022 Feb; 27(2):664-674. PubMed ID: 34856395
[TBL] [Abstract][Full Text] [Related]
10. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
[TBL] [Abstract][Full Text] [Related]
11. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
Mohamed AA; Thomsen A; Follo M; Zamboglou C; Bronsert P; Mostafa H; Amen A; Mekawy M; Grosu AL; Brunner TB
Strahlenther Onkol; 2021 Jan; 197(1):27-38. PubMed ID: 32705304
[TBL] [Abstract][Full Text] [Related]
12. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Behmoaram E; Bijian K; Jie S; Xu Y; Darnel A; Bismar TA; Alaoui-Jamali MA
Am J Pathol; 2008 Nov; 173(5):1540-50. PubMed ID: 18832579
[TBL] [Abstract][Full Text] [Related]
13. Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer.
Wu CC; Pan MR; Shih SL; Shiau JP; Wu CC; Chang SJ; Kao CN; Chen FM; Hou MF; Luo CW
Biomed Pharmacother; 2023 Jul; 163():114732. PubMed ID: 37254289
[TBL] [Abstract][Full Text] [Related]
14. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
Begum A; Ewachiw T; Jung C; Huang A; Norberg KJ; Marchionni L; McMillan R; Penchev V; Rajeshkumar NV; Maitra A; Wood L; Wang C; Wolfgang C; DeJesus-Acosta A; Laheru D; Shapiro IM; Padval M; Pachter JA; Weaver DT; Rasheed ZA; Matsui W
PLoS One; 2017; 12(7):e0180181. PubMed ID: 28692661
[TBL] [Abstract][Full Text] [Related]
15. Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression.
Rigiracciolo DC; Cirillo F; Talia M; Muglia L; Gutkind JS; Maggiolini M; Lappano R
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562737
[TBL] [Abstract][Full Text] [Related]
16. Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Stone RL; Baggerly KA; Armaiz-Pena GN; Kang Y; Sanguino AM; Thanapprapasr D; Dalton HJ; Bottsford-Miller J; Zand B; Akbani R; Diao L; Nick AM; DeGeest K; Lopez-Berestein G; Coleman RL; Lutgendorf S; Sood AK
Cancer Biol Ther; 2014 Jul; 15(7):919-29. PubMed ID: 24755674
[TBL] [Abstract][Full Text] [Related]
17. FAK signaling in human cancer as a target for therapeutics.
Lee BY; Timpson P; Horvath LG; Daly RJ
Pharmacol Ther; 2015 Feb; 146():132-49. PubMed ID: 25316657
[TBL] [Abstract][Full Text] [Related]
18. Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.
Levy A; Alhazzani K; Dondapati P; Alaseem A; Cheema K; Thallapureddy K; Kaur P; Alobid S; Rathinavelu A
Curr Cancer Drug Targets; 2019; 19(3):179-188. PubMed ID: 29984656
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW
Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606
[TBL] [Abstract][Full Text] [Related]
20. FAK displacement from focal adhesions: a promising strategy to target processes implicated in cancer progression and metastasis.
Antoniades I; Kyriakou M; Charalambous A; Kalalidou K; Christodoulou A; Christoforou M; Skourides PA
Cell Commun Signal; 2021 Jan; 19(1):3. PubMed ID: 33413438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
